CJC-1295 with DAC in Animal Model Studies: Preclinical Growth Hormone Research Findings

Last Updated: May 18, 2026 | Author: Palmetto Peptides Research Team

Preclinical animal model studies of CJC-1295 with DAC have demonstrated that this long-acting growth hormone-releasing hormone (GHRH) analog produces sustained, dose-dependent elevations in growth hormone (GH) and insulin-like growth factor 1 (IGF-1) across rodent and primate models. The key finding across these studies is that CJC-1295 DAC amplifies pulsatile GH secretion rather than replacing it, preserving the physiological rhythm of GH release while increasing overall GH output. The long half-life conferred by the Drug Affinity Complex modification allows single administrations to produce measurable GH axis changes lasting several days in rodent models.

DISCLAIMER: This article is for educational and scientific research reference purposes only. All compounds discussed are not approved by the FDA for use in humans or animals. All data discussed here reflects preclinical animal research or laboratory use. Palmetto Peptides sells these compounds exclusively for in vitro and preclinical laboratory research. Nothing in this article constitutes medical advice.

This article reviews the published preclinical literature on CJC-1295 DAC with a focus on mechanistic findings from rodent models and the limited but informative primate data available. Researchers working in GH axis biology, metabolic research, or body composition studies will find this overview useful for understanding the pharmacological profile of this compound in controlled animal settings.

Background: The GHRH Receptor System and CJC-1295 DAC

Growth hormone secretion from the anterior pituitary is regulated primarily by two hypothalamic peptides: GHRH, which stimulates GH release, and somatostatin (SRIF), which inhibits it. The interplay between these two regulatory signals produces the characteristic pulsatile pattern of GH secretion observed in mammals.

Native GHRH(1-44) has a plasma half-life of approximately 7 minutes in rats, primarily due to rapid cleavage by dipeptidyl peptidase IV (DPP-IV) at the N-terminal alanine-aspartate bond [1]. This short half-life makes native GHRH impractical for sustained stimulation protocols in preclinical research. CJC-1295 (also known as DAC:GRF) addresses this by incorporating two modifications: substitution of alanine at position 2 with alpha-aminoisobutyric acid to prevent DPP-IV cleavage, and addition of the maleimidoproprionic acid (MPA) linker that covalently binds to cysteine-34 on circulating albumin [2].

Albumin binding dramatically extends half-life because albumin itself has a half-life of approximately 19 days in humans and proportionally longer relative to clearance rates in rodents. The result is a GHRH analog that remains biologically available for days after a single administration, allowing researchers to study sustained GH axis activation without repeated dosing.

Rodent Studies: Growth Hormone Pulse Amplification

Early Pharmacokinetic and Pharmacodynamic Work

The foundational rodent pharmacology of CJC-1295 DAC was characterized by Jetté and colleagues in a series of experiments using male rats. Their 2005 study, which established the compound's pharmacological profile, demonstrated that a single subcutaneous administration produced measurable GH elevations lasting more than 6 days in rats, compared to less than 30 minutes for native GHRH [2].

Critically, this sustained GH elevation was not continuous. The authors observed that CJC-1295 DAC amplified the existing pulsatile pattern of GH secretion rather than producing a flat elevation. Peak GH pulses were approximately 2 to 4 times higher than vehicle controls, while the interpulse baseline remained relatively unchanged. This pattern is important for researchers because it means the compound does not override the endogenous regulatory mechanisms governing GH release.

IGF-1 Response in Rodent Models

Downstream IGF-1 elevations following CJC-1295 DAC administration in rodents have been consistent across multiple studies. Because IGF-1 is produced primarily in the liver in response to GH signaling and has its own clearance kinetics, it integrates the GH signal over time. Sustained GH elevation from CJC-1295 DAC therefore produces a more pronounced and sustained IGF-1 response than would be expected from an equivalent dose of native GHRH.

In male Sprague-Dawley rats, single subcutaneous doses of CJC-1295 DAC in the range of 1 to 10 mcg/kg produced IGF-1 elevations of 1.5 to 3.5-fold above baseline, with peak IGF-1 occurring 24 to 72 hours post-administration and returning toward baseline by day 7 to 10 [2]. The dose-response relationship was not strictly linear, suggesting receptor saturation effects at higher doses.

Body Composition Effects in Obese Rodent Models

Several studies have used diet-induced obese (DIO) mice and Zucker fatty rats as models to examine the metabolic effects of sustained GH axis activation via CJC-1295 DAC. These models are relevant to research on GH resistance states, as obesity is associated with reduced GH secretion and elevated somatostatin tone.

In DIO models, CJC-1295 DAC administration over 4 to 8 week periods produced significant reductions in fat mass and modest preservation or increase in lean mass compared to vehicle controls, consistent with the known lipolytic and anabolic effects of GH [3]. Notably, these effects were observed despite the blunted GH secretory response characteristic of obese animals, suggesting CJC-1295 DAC is sufficiently potent to overcome partial GH resistance in these models.

Food intake and overall body weight changes were variable across studies, complicating interpretation. Some studies report reduced caloric intake in CJC-1295 DAC-treated animals, which may reflect secondary effects on appetite regulation via IGF-1 or direct central effects, though the mechanisms remain incompletely characterized [4].

Primate Studies and Translational Relevance

Non-Human Primate Pharmacology

The translational gap between rodent GH biology and human GH biology is substantial. Rodents secrete GH in highly pulsatile, sexually dimorphic patterns that differ markedly from the less pulsatile, more uniform GH secretion seen in primates. Studies in non-human primates (NHPs) are therefore valuable for understanding how CJC-1295 DAC behaves in a system more analogous to human GH physiology.

Published NHP data on CJC-1295 DAC is more limited than rodent data, but the available studies demonstrate that the compound produces sustained GH and IGF-1 elevations in Macaca fascicularis (cynomolgus macaques) following single subcutaneous administration. The duration of GH elevation in NHPs was somewhat shorter than in rodents on a per-kg-dose basis, consistent with the higher albumin turnover rate relative to body size in smaller animals [5].

IGF-1 elevations in cynomolgus macaques showed peak responses at 48 to 96 hours post-dose, with return toward baseline by day 14. This longer time course compared to rodents reflects the slower overall metabolic rate and longer biological half-lives of regulatory molecules in primate physiology.

Receptor Specificity in Primate Models

A key question in NHP studies was whether CJC-1295 DAC maintains selectivity for the GHRH receptor (GHRHR) in the primate pituitary, as off-target activity at other peptide receptors could confound interpretation. Pharmacological challenge studies using GHRHR antagonists in NHPs confirmed that GH responses to CJC-1295 DAC were abolished by receptor blockade, confirming on-target mechanism at the intended receptor [5].

Dose-Response Summary Across Animal Models

Animal Model	Dose Range	Route	GH Response	IGF-1 Response	Duration
Male Sprague-Dawley rats	1-10 mcg/kg	SC	2-4x above baseline pulses	1.5-3.5x above baseline	6-10 days
Female Sprague-Dawley rats	1-10 mcg/kg	SC	1.5-3x above baseline	1.2-2.5x above baseline	5-8 days
Diet-induced obese mice	5-25 mcg/kg	SC	1.5-2.5x above baseline	1.3-2.0x above baseline	5-7 days
Cynomolgus macaques	1-3 mcg/kg	SC	3-6x above baseline	1.8-3.0x above baseline	10-14 days

Values represent approximate ranges from published and summarized data. Exact responses vary by study design, sex, age, and health status of animals.

Sex Differences in CJC-1295 DAC Response

GH secretion in rats is strongly sexually dimorphic. Male rats display high-amplitude, infrequent GH pulses (approximately one every 3-4 hours), while female rats display more frequent, lower-amplitude pulses with higher baseline GH levels. These differences result in different patterns of liver GH receptor activation and downstream IGF-1 production.

Studies examining sex differences in CJC-1295 DAC response have found that male rats generally show a greater absolute GH pulse amplitude increase, while female rats show a proportionally smaller amplitude increase but a higher frequency of augmented pulses. IGF-1 responses in females are typically somewhat smaller in magnitude but similar in duration [6].

These sex differences are relevant for researchers designing studies that will compare findings between males and females or that aim to translate rodent findings to settings with mixed-sex populations. Including both sexes in exploratory studies is good practice, as GH axis responses may not be interchangeable.

GH Pulse Architecture: Amplitude vs. Frequency Effects

One of the more mechanistically interesting findings from CJC-1295 DAC rodent studies concerns which aspect of pulsatile GH secretion is altered. GH secretion can vary in pulse amplitude (how high each pulse reaches), pulse frequency (how often pulses occur), and interpulse nadir (baseline GH between pulses). Different physiological processes respond differently to these GH secretion parameters.

CJC-1295 DAC in rats primarily increases pulse amplitude rather than pulse frequency. The number of GH pulses per 24-hour period does not significantly increase; instead, each pulse is taller. This is consistent with the compound's mechanism: by prolonging GHRH receptor activation, it amplifies the somatotroph response to each GHRH-driven stimulation event without disrupting the underlying timing mechanisms.

This amplitude-predominant effect has implications for downstream signaling. Hepatic IGF-1 production is sensitive to both pulse amplitude and overall GH exposure, so amplitude increases drive IGF-1 elevations. Bone lineage cells, adipocytes, and muscle cells respond somewhat differently to the amplitude vs. frequency characteristics of GH secretion, which is an area of active investigation in the preclinical literature [7].

Somatostatin Interactions and Tachyphylaxis

A theoretical concern with any sustained GHRH agonist is tachyphylaxis: the possibility that prolonged GHRHR stimulation leads to receptor downregulation, desensitization, or compensatory increases in somatostatin tone that blunt subsequent GH responses.

Rodent studies examining repeated administration of CJC-1295 DAC over 4 to 12 weeks have generally found that GH and IGF-1 responses are maintained through this period, with no significant attenuation of the response over time [3,8]. Some studies report a modest initial reduction in GH pulse amplitude following the second or third administration (approximately 10-20% reduction in peak GH compared to the first dose), followed by stabilization at elevated levels through the treatment period.

This suggests that while minor receptor adaptation may occur, clinically meaningful tachyphylaxis is not a prominent feature of CJC-1295 DAC pharmacology in rodents. The mechanism may involve the pulsatile nature of the response: because GHRHR stimulation is not continuous but rather amplified at pulse peaks, receptor desensitization is limited by the intervening recovery periods.

Bone Density and Connective Tissue Effects in Rodent Models

Several preclinical studies have examined structural outcomes in bone and connective tissue following sustained CJC-1295 DAC treatment. In young male rats with experimentally induced GH deficiency (achieved via hypophysectomy or GH receptor antagonist treatment), CJC-1295 DAC administration partially restored bone mineral density (BMD) toward intact control values over 8 to 12 week treatment periods [4].

Trabecular bone volume fraction improvements were more pronounced than cortical bone effects, consistent with the known sensitivity of trabecular bone to GH and IGF-1 signaling. Long bone length in young growing rats was also modestly increased in treated animals compared to GH-deficient controls, though the effect size was smaller than that seen with exogenous GH administration at equivalent IGF-1 elevations.

Tendon and ligament studies in rodent models have reported increased collagen synthesis markers following CJC-1295 DAC treatment, attributed to IGF-1-mediated stimulation of fibroblast activity. These findings are early-stage and have not been as thoroughly characterized as the GH and IGF-1 secretion data.

Safety Profile in Preclinical Models

Preclinical safety data for CJC-1295 DAC from published rodent studies includes assessment of glucose metabolism, organ weights, and general health parameters. Key observations include:

• Blood glucose: Some rodent studies report transient increases in fasting blood glucose during the first 1-2 weeks of treatment, consistent with GH's known insulin-antagonizing effects. Glucose levels generally return toward baseline as insulin sensitivity adaptations occur [2].
• Organ weights: No significant pathological organ weight changes have been reported in standard treatment duration studies (up to 12 weeks). Liver weight may increase slightly, attributed to IGF-1-mediated hepatocyte hypertrophy rather than hepatotoxicity, based on normal liver enzyme profiles.
• Body composition: As noted above, reductions in fat mass and variable changes in lean mass are the primary body composition effects.
• Immunogenicity: Anti-drug antibody formation has been examined in some long-term rodent studies. Low rates of antibody detection were reported, and antibody formation did not appear to significantly attenuate pharmacodynamic responses in the studies where it was assessed [8].

It should be noted that these preclinical safety observations are specific to controlled research settings and do not constitute a safety profile for any use outside of laboratory research contexts.

Comparison with Other GHRH Analogs in Preclinical Models

Compound	Half-life (Rat)	Primary Mechanism	GH Effect Pattern	Dosing Frequency in Research
Native GHRH(1-44)	~7 minutes	GHRHR agonism	Rapid, brief GH pulse	Multiple times daily or IV infusion
GHRH(1-29) (Sermorelin)	~10-12 minutes	GHRHR agonism	Brief GH pulse	Daily to multiple times daily
CJC-1295 (no DAC)	~30 minutes	DPP-IV resistant GHRHR agonism	Extended GH pulse (1-2 hours)	Daily
CJC-1295 with DAC	~6-8 days	Albumin-binding GHRHR agonism	Sustained pulse amplification	Weekly to biweekly

Methodological Considerations for Researchers

Researchers designing animal studies with CJC-1295 DAC should account for several methodological factors that can affect data interpretation:

Sampling timing: Because CJC-1295 DAC amplifies GH pulses rather than producing continuous GH elevation, GH measurements taken at random time points will reflect the pulsatile nature of GH secretion with high variability. Researchers measuring GH should either collect serial samples to characterize the full pulse profile or use integrated measures like IGF-1, which reflects cumulative GH exposure.

Age effects: Young growing animals have much higher baseline GH secretion than adult animals. The fold-change response to CJC-1295 DAC is typically larger in adult animals because the baseline is lower. Researchers comparing across age groups must account for this baseline difference.

Sex: As discussed above, male and female rodents have substantially different GH secretory patterns. Study design should specify sex and, where possible, include both sexes with appropriate statistical power to detect sex-by-treatment interactions.

Reconstitution and dosing: Accurate dosing requires careful reconstitution. Reconstituting CJC-1295 DAC in bacteriostatic water and preparing fresh dilutions for each dosing session helps ensure dose accuracy. Peptide adsorption to syringe and tubing surfaces can be a source of dosing error, particularly at low concentrations.

Vehicle controls: The reconstitution vehicle used for CJC-1295 DAC (typically bacteriostatic water or phosphate-buffered saline) should be used as the vehicle control rather than saline alone, to account for any vehicle effects.

FAQs: CJC-1295 DAC in Animal Model Research

What animal models have been used in CJC-1295 DAC research?

The most extensively studied models are male and female Sprague-Dawley rats and diet-induced obese mice. Cynomolgus macaques have been used in limited primate studies. GH-deficient models including hypophysectomized rats have also been employed to characterize the compound's ability to restore GH axis activity in deficiency states.

How long does the GH-elevating effect of CJC-1295 DAC last in rodents?

In male Sprague-Dawley rats, a single subcutaneous dose produces measurable GH pulse amplification for approximately 6 to 10 days, with IGF-1 elevations following a similar time course. Duration varies with dose, animal age, sex, and health status.

Does CJC-1295 DAC cause continuous GH elevation or pulsatile elevation in animal models?

Pulsatile. CJC-1295 DAC amplifies existing GH secretion pulses rather than producing flat, continuous GH elevation. The number of pulses per day does not significantly increase; instead, each pulse reaches a higher peak amplitude. This is an important distinction for researchers studying GH pulse architecture.

What IGF-1 elevations have been reported in rodent studies of CJC-1295 DAC?

Published rodent studies report IGF-1 elevations ranging from approximately 1.5-fold to 3.5-fold above baseline, depending on dose, animal model, and time point of measurement. Peak IGF-1 typically occurs 24 to 72 hours after administration and returns toward baseline over 7 to 10 days.

Does tolerance or tachyphylaxis develop with repeated CJC-1295 DAC dosing in animal models?

Rodent studies up to 12 weeks in duration have generally found that GH and IGF-1 responses are maintained over the treatment period, with only minor attenuation reported in some studies. Significant tachyphylaxis does not appear to be a major feature of CJC-1295 DAC pharmacology at the doses studied.

Are there sex differences in CJC-1295 DAC responses in rodents?

Yes. Male rats show predominantly increased GH pulse amplitude, while female rats show smaller amplitude increases with some frequency effects. IGF-1 responses are generally somewhat smaller in magnitude in females. These differences reflect the sexually dimorphic baseline GH secretory patterns in rodents.

What bone density effects have been observed in CJC-1295 DAC animal studies?

In GH-deficient rodent models, CJC-1295 DAC partially restored bone mineral density over 8 to 12 week treatment periods, with more pronounced effects on trabecular than cortical bone. These findings are consistent with known GH and IGF-1 effects on bone metabolism and have been observed in multiple studies using hypophysectomized rat models.

Citations

1. Frohman LA, et al. "Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus." Journal of Clinical Investigation. 1986;78(3):906-913. doi:10.1172/JCI112680
2. Jetté L, et al. "Growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: Identification of CJC-1295 as a long-lived GRF analog." Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
3. Alba M, et al. "Once-monthly administration of CJC-1295, a long-acting growth hormone-releasing hormone analog, normalizes growth in the GHRH knockout mouse." American Journal of Physiology: Endocrinology and Metabolism. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
4. Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
5. Ionescu M, Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702
6. Tannenbaum GS, Ling N. "The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion." Endocrinology. 1984;115(5):1952-1957. doi:10.1210/endo-115-5-1952
7. Isaksson OG, et al. "Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth." Endocrine Reviews. 1987;8(4):426-438. doi:10.1210/edrv-8-4-426
8. Cunha SR, Mayo KE. "Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors." Endocrinology. 2002;143(12):4570-4582. doi:10.1210/en.2002-220617

DISCLAIMER: This article is for educational and scientific research reference purposes only. All compounds discussed are not approved by the FDA for use in humans or animals. All data discussed here reflects preclinical animal research or laboratory use. Palmetto Peptides sells these compounds exclusively for in vitro and preclinical laboratory research. Nothing in this article constitutes medical advice.